Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia
Discuss the effectiveness and safety of cord blood microtransplantation for treatment of acute myeloid leukemia
Safety Issues|Efficiency
BIOLOGICAL: microtransplantation
complete remission rate, Bone marrow \<5% blasts； Absolute neutrophil count \>1000/mcL； Platelets ≥100,000/mcL；No residual evidence of extramedullary disease., 1 month|time of hematopoietic recovery, Absolute neutrophil count \>500/mcL; Platelets ≥20,000/mcL, 1 month
time to progression, Measured from complete remission to the relapse, 2 year
diease free survival, Measured from complete remission to the date of death or the date of last follow-up examination., 2 year|overall survival, Measured from the date of beginning therapy to the date of death or the date of last follow-up examination., 2 year|rate of early mortality, Death within 4 weeks after initiation of induction therapy, 1 month
The investigators conducted a prospective, single center clinical trial to dissuss the outcomes and toxicities of HLA-mismatched cord blood infusion after chemotherapy (microtransplantation) in older patients with acute myeloid leukemia (AML)